Brief: Tscan Therapeutics Announces Positive Initial Data From Phase 1 Study In Patients With Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
22/06/2026 12:45
BRIEF-Tscan Therapeutics Announces Positive Initial Data From Phase 1 Study In Patients With Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation June 22 (Reuters) - TScan Therapeutics Inc TCRX.O:
TSCAN THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM COHORT C OF ONGOING ALLOHA™ PHASE 1 STUDY EVALUATING TSC-101 IN PATIENTS WITH HEME MALIGNANCIES UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
TSCAN THERAPEUTICS - TSC-101 CONTINUES TO BE WELL-TOLERATED
TSCAN THERAPEUTICS - ON TRACK TO ENROLL FIRST PATIENT IN PHASE 3 ALLOHA-2 STUDY OF TSC-101 THIS MONTH
Source text: ID:nGNX11tWRq
Further company coverage: TCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing